PROTOCOL REVIEW AND MONITORING SYSTEM ABSTRACT The Protocol Review and Monitoring System (PRMS) is critical to Huntsman Cancer Institute's (HCI) goal to maintain a vibrant clinical research portfolio of scientifically excellent clinical trials for our patients; support the clinical research efforts of our faculty; and improve strategies for cancer detection, diagnosis, treatment, and prevention through our clinical research activities. PRMS functions at HCI are fulfilled by the Clinical Cancer Investigations Committee (CCIC). HCI's robust CCIC enables us to review the scientific merit of proposed clinical studies, evaluate the contribution of proposed protocols to the strategic aims of our Cancer Center, and assess the scientific progress of ongoing studies. The CCIC 1) conducts thorough scientific review of all cancer-related studies performed at HCI, 2) prioritizes research protocols and prevents protocol competition, 3) prioritizes protocols for access to HCI Clinical Trials Office support, 4) evaluates ongoing protocols for continued progress toward accrual goals, 5) reviews and approves protocol amendments, and 6) closes under-accruing trials. Before a study can be presented to the CCIC, it must be submitted to the appropriate Multidisciplinary Disease Group (MDG) for review, approval, and priority rating by the community of HCI physicians in that area. To support HCI's institutional commitment to clinical research, in the current reporting period HCI implemented a Institutional Protocol Development Committee (IPDC) to aid in the development of high quality investigator-intitated trials and a two-stage review process to facilitate rigorous and efficient approval of studies. In stage one review, trials are evaluated by the Feasibility Administrative Review (FAR) committee, which comprises the administrative leadership of the Clinical Protocol and Data Management/Clinical Trials Office. The FAR committee evaluates studies for budget (adequate funding), regulatory, personnel support (clinical research coordinators and research data coordinators), accrual goals, principal investigator (PI) and MDG accrual performance, and completed PI required trainings. Initial review by the FAR committee ensures that studies submitted for stage two CCIC review are strong, with all administrative concerns resolved. In stage two, the CCIC committee, which has broad and extensive expertise in oncology, reviews the scientific merit of new clinical protocols and assesses progress of open studies. The CCIC committee includes representatives from medical oncology, surgical oncology, pediatric hematology-oncology, radiation oncology, biostatistics, pharmacology, pathology, basic science, population sciences, and research nursing, as well as a patient advocate and HCI's CEO/Director Mary Beckerle, PhD, as an ex-officio member.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA042014-29
Application #
9478885
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
29
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Utah
Department
Type
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Pishas, Kathleen I; Drenberg, Christina D; Taslim, Cenny et al. (2018) Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Mol Cancer Ther 17:1902-1916
Blackburn, Brenna E; Ganz, Patricia A; Rowe, Kerry et al. (2018) Reproductive and gynecological complication risks among thyroid cancer survivors. J Cancer Surviv 12:702-711
Wu, Yelena P; Aspinwall, Lisa G; Nagelhout, Elizabeth et al. (2018) Development of an Educational Program Integrating Concepts of Genetic Risk and Preventive Strategies for Children with a Family History of Melanoma. J Cancer Educ 33:774-781
Kim, Hyung-Seok; McKnite, Autumn; Xie, Yuanyuan et al. (2018) Fibronectin type III and intracellular domains of Toll-like receptor 4 interactor with leucine-rich repeats (Tril) are required for developmental signaling. Mol Biol Cell 29:523-531
Spiker, William Ryan; Brodke, Darrel S; Goz, Vadim et al. (2018) Evidence of an Inherited Predisposition for Spinal Cord Tumors. Global Spine J 8:340-344
Ye, Zhizhou; Ayer, Donald E (2018) Ras Suppresses TXNIP Expression by Restricting Ribosome Translocation. Mol Cell Biol :
Fuller, Andrew K; Bice, Benjamin D; Venancio, Ashlee R et al. (2018) A Method to Define the Effects of Environmental Enrichment on Colon Microbiome Biodiversity in a Mouse Colon Tumor Model. J Vis Exp :
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Faham, Najme; Zhao, Ling; Welm, Alana L (2018) mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. NPJ Breast Cancer 4:36
Rengifo-Cam, William; Shepherd, Hailey M; Jasperson, Kory W et al. (2018) Colon Pathology Characteristics in Li-Fraumeni Syndrome. Clin Gastroenterol Hepatol 16:140-141

Showing the most recent 10 out of 1193 publications